Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation

Journal of the American Society of Echocardiography

Volumn 14, Issue 3, 2001, Pages 200-208

  Murray, R Daniel ^b   Deitcher, Steven R ^b   Shah, Amrik ^b   Jasper, Susan E ^b   Bashir, Mohammed ^b   Grimm, Richard A ^b   Klein, Allan L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN;

ARTICLE; CARDIOVERSION; COST BENEFIT ANALYSIS; ECHOGRAPHY; ECONOMICS; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ENOXAPARIN; HUMANS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 85047682747     PISSN: 08947317     EISSN: None     Source Type: Journal    
DOI: 10.1067/mje.2001.109505     Document Type: Article

References (47)

1. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29:469-89.
2. Gosselink AT, Crijns HJ, van den Berg MP, van den Broek SA, Hillege H, Landsman ML, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-6.
3. Aberg H, Cullhed I. Direct current conversion of atrial fibrillation: long-term results. Acta Med Scand 1968;184:433-40.
4. Resnekov L. Haemodynamic studies before and after electrical conversion of atrial fibrillation and flutter to sinus rhythm. Br Heart J 1967;29:700-8.
5. Selzer A, Kelly J, Johnson RB, Kerth WJ. Immediate and long-term results of electrical cardioversion of arrhythmias. Prog Cardiovasc Dis 1966;9:90-104.
6. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352S-359S.
7. Laupacis A, Albers G, Dalen J, Dunn M, Jacobson A, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114:579S-589S.
8. Mayet J, Wasan B, Sutton GC. Cardioversion of atrial arrhythmias: audit of anticoagulation management. J Royal Coll Phys London 1997;31:313-6.
9. Schlicht JR, Davis RC, Naqi K, Cooper W, Rao BV. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Arch Intern Med 1996;156:290-4.
10. Murray RD, Jasper SE, Goodman A, Becker ER, Culler SD, Weintraub WS, et al. Cost analysis model of low molecular weight heparin for antithrombotic therapy in patients undergoing TEE-guided cardioversion from atrial fibrillation [abstract], J Am Coll Cardiol 1999;33:295A.
11. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995;49:388-410.
12. Murray RD, Goodman AS, Lieber EA, Jasper SE, Grimm RA, Garcia MJ, et al. National use of the transesophageal echocardiography guided approach to cardioversion for patients in atrial fibrillation. Am J Cardiol 2000;85:239-44.
13. Cohen M, Deniers C, Gurfinkle EP, Turpie AGG, Eromell GJ, Goodman S, et al, for the ESSENCE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
14. Mark D, Cowper P, Berkowitz S, Davidson-Ray BA, DeLong ER, Turpie AGG, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Circulation 1998;97:1702-7.
15. Klein AL, Grimm RA, Black IW, Leung DY, Chung MK, Vaughn SE, et al. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study - a randomized, controlled trial. Assessment of cardioversion using transesophageal echocardiography. Ann Intern Med 1997;126: 200-9.
16. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-16.
17. Henry WL, Morganroth J, Pearlman AS, Clark CE, Redwood DR, Itscoitz SB. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976;53:273-9.
18. Rokseth R, Storstein D. Quinidine therapy of chronic auricular fibrillation: the occurrence and mechanism of syncope. Arch Intern Med 1963;111:184-9.
19. Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986;112:1039-43.
20. Morris JJ, Peter RH, McIntosh HD. Electrical cardioversion of atrial fibrillation: immediate and long-term results and selection of patients. Am J Cardiol 1964;14:94-100.
21. Oram S, Davies JPH. Further experience of electrical cardioversion of atrial fibrillation to sinus rhythm: analysis of 100 patients. Lancet 1964;1:1294-8.
22. ACUTE Investigators. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE multicenter study). Am J Cardiol 1998;81: 877-83.
23. ACUTE Investigators. Transesophageal echocardiography guided cardioversion of patients in atrial fibrillation undergoing cardioversion: eight-week clinical outcomes. Late-Breaking Clinical Trial presented at the American College of Cardiology Scientific Sessions, Anaheim, Calif. March 14, 2000.
24. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997;29:122-30.
25. van der Meer F, Rosendaal F, Vandenbroucke J, Briet E. Bleeding complications in oral anticoagulation therapy. Arch Intern Med 1993;153:1557-62.
26. Eckman MH, Levine HJ, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1995;108:457S-470S.
27. Taylor T, Davis P, Torner J, Holmes J, Meyer J, Jacobson M. Lifetime cost of stroke in the United States. Stroke 1996;27: 1459-66.
28. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. Brit Med J 1992;305:1457-60.
29. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
30. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
31. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep venous thrombosis. N Engl J Med 1996;334:677-81.
32. Cohen IS, Ezekowitz MD. Prevention of thromboembolism in patients with atrial fibrillation. Cardiol Clin 1996;14:537-42.
33. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995;129: 1204-15.
34. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995;25:1354-61.
35. Grimm RA, Agler DA, Vaughn SE, Scalia G, Murray RD, Klein AL. Transesophageal echocardiography guided cardioversion of atrial fibrillation: results from the ACUTE registry [abstract]. J Am Coll Cardiol 1998;31:354A.
36. Orsinelli DA, Pearson AC. Usefulness of transesophageal echocardiography to screen for left atrial thrombus before elective cardioversion for atrial fibrillation. Am J Cardiol 1993;72:1337-9.
37. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93:1262-77.
38. Mark D, Simins T. Fundamentals of economic analysis. Am Heart J 1999;137:S38-S40.
39. Mark D. Medical economics and health policy issues for interventional cardiology. In: Topol E, editor. Textbook of interventional cardiology. Philadelphia: WB Saunders; 1993. p. 1323-53.
40. Seto TB, Taira DA, Manning WJ. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effective analysis. J Am Soc Echocardiogr 1999;12:508-16.
41. Harenberg J, Weuster B, Pfitzer M, Dempfle CE, Stehle G, Kubler W, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Sem Thrombos Hemostas 1993;19(Suppl):116-21.
42. Roijer A, Eskilsson J, Olsson B. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter: selection of a low-risk group for immediate cardioversion. Eur Heart J 2000;21:837-47.
43. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
44. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep venous thrombosis after total hip replacement. Ann Intern Med 1993;119:1105-12.
45. Menzin J, Colditz GA, Ragan MM, Richer RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep venous thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
46. Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS. Economic analysis of low-dose heparin vs the low molecular weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med 1999; 159:1221-8.
47. Murray RD, Shah A, Jasper SE, Goodman A, Deitcher SR, Katz W, et al, for the ACUTE II Pilot Study Investigators. Design of a pilot study to test the feasibility, general safety, and economics of a transesophageal echocardiography guided low molecular weight heparin (enoxaparin) approach to cardioversion of patients in atrial fibrillation: The ACUTE II Study. Am Heart J 2000;139:E5.